Format

Send to

Choose Destination
Curr Opin Pharmacol. 2014 Jun;16:148-56. doi: 10.1016/j.coph.2014.05.007. Epub 2014 Jun 9.

Changing face of β2-adrenergic and muscarinic receptor therapies in asthma.

Author information

1
Division of Respirology, Department of Medicine and Department of Biomedical & Molecular Sciences, Queen's University, Kingston, Ontario, Canada.
2
Division of Respirology, Department of Medicine and Department of Biomedical & Molecular Sciences, Queen's University, Kingston, Ontario, Canada. Electronic address: fisherjt@queensu.ca.

Abstract

Despite current available treatment options, a significant proportion of patients with asthma remain uncontrolled and asthma pharmacotherapy continues to evolve. β2-Adrenergic receptor agonists play a major role as bronchodilators in asthma therapy, although new perspectives reflect the potential for bias G-protein coupled receptor signaling pathways. Due to the success of muscarinic antagonists in chronic obstructive pulmonary disease, and the elucidation that muscarinic receptors play a role in airway remodeling, muscarinic receptors represent an attractive therapeutic target in asthma. Although short-acting muscarinic antagonists are currently limited to their use in acute asthma and as alternative bronchodilators in individuals who experience side effects with β2-agonists, recent clinical trials indicate that the long-acting muscarinic antagonist, tiotropium, deserves consideration as a potential therapeutic agent for select populations. The continued evolution of anticholinergic therapy in asthma will require appropriately designed studies to assess mechanisms, efficacy and safety in asthma.

PMID:
24922602
DOI:
10.1016/j.coph.2014.05.007
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center